Home > Insider Trading > Filing (0001193805-10-000961)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410098	Cormedix Inc.	CRMD	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1374805	H Russell Ellison	C/O Cormedix Inc. 86 Summit Avenue, Suite 301 Summit NJ 079013647		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Acquisiton	2010-03-30	160,000	$0.00	160,000	No	4	P	Indirect	By Global Paramount BioFund, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Global Paramount BioFund, LP

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, $0.001 Par Value Per Share	Stock option (right to buy)	Acquisiton	2010-03-30	20,000	$0.00	20,000	$3.13
Common Stock, $0.001 Par Value	Warrants issued as a part of Units	Acquisiton	2010-03-30	80,000	$0.00	80,000	$3.44

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,000		2020-03-30	No	4	A	Direct
80,000		2015-03-24	No	4	P	Indirect

Footnotes

These securities were issued as a part of 80,000 Units purchased by Global Paramount BioFund, LP (the ''Fund'') directly from the underwriters in the Company's initialpublic offering, which closed on March 30, 2010. The Units were purchased at $6.50 per Unit, the initial public offering price. Each Unit consists of two shares ofcommon stock and a warrant to purchase one share of common stock.
The Fund is the direct owner of the subject securities. Mr. Ellison is a managing member of Global BioFund GP, LLC, the general partner of the Fund, and a portfoliomanager of Global Bio Asset Management, LP, the investment manager of the Fund. Mr. Ellison disclaims beneficial ownership of such securities, except to the extentof his pecuniary interest therein, if any. This report shall not be deemed an admission that Mr. Ellison is the beneficial owner of the securities for purposes of Section16 of the Securities Exchange Act of 1934, as amended or for any other purpose.
These options vest as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.
These warrants will become exercisable upon the earlier to occur of the expiration of the underwriters' over allotment option with respect to the Company's initial public offering, or the exercise in full of such over allotment option.